Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series

Jaspreet Chahal, Alison T Stopeck, Kathryn Clarke, Robert B Livingston, Pavani Chalasani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Leptomeningeal carcinomatosis (LMC) secondary to metastatic breast cancer (MBC) has increased in incidence with improved systemic disease control. Current treatment options include radiation therapy (to symptomatic sites) and systemic treatment [intrathecal (IT) or intravenous (IV) chemotherapy]. Methotrexate (MTX), thiotepa and cytarabine are the most commonly used IT agents, while high-dose MTX is the most common IV regimen. While IT treatments are generally well tolerated, complications like chemical meningitis, leukoencephalopathy, etc. occur. LMC may cause a breakdown in the blood–brain barrier and thus allow systemic agents to penetrate; however, efficacy is reported only for agents administered at high doses (MTX). We report our institution’s experience in using IV thiotepa as treatment for LMC secondary to MBC. We conducted a retrospective chart review of 13 patients with MBC who developed LMC and treated with IV thiotepa at our institution. It was administered at 40 mg/m<sup>2</sup> every 21 days; median number of thiotepa cycles administered was 5 with the major dose-limiting toxicity being myelosuppression. Four had partial response, 3 had stable disease and 6 had progressive disease. The 6-month survival rate was 69 % and 1-year survival rate was 31 %. Despite retrospective nature of our case series, we found the use of IV thiotepa as sole treatment for LMC in patients with MBC to be well tolerated, easily administered in the ambulatory setting, and with efficacy comparable to the other chemotherapeutic agents commonly used in the treatment of LMC. This regimen warrants further investigation in prospective studies.

Original languageEnglish (US)
Pages (from-to)1691-1693
Number of pages3
JournalNeurological Sciences
Volume36
Issue number9
DOIs
StatePublished - Sep 27 2015

Fingerprint

Meningeal Carcinomatosis
Thiotepa
Breast Neoplasms
Methotrexate
Therapeutics
Survival Rate
Leukoencephalopathies
Cytarabine
Meningitis
Radiotherapy
Prospective Studies
Drug Therapy
Incidence

Keywords

  • Intravenous chemotherapy
  • Leptomeningeal carcinomatosis
  • Metastatic breast cancer
  • Thiotepa

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis : case series. / Chahal, Jaspreet; Stopeck, Alison T; Clarke, Kathryn; Livingston, Robert B; Chalasani, Pavani.

In: Neurological Sciences, Vol. 36, No. 9, 27.09.2015, p. 1691-1693.

Research output: Contribution to journalArticle

@article{3718ff70a8ca408e9ec63c807ea6556a,
title = "Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case series",
abstract = "Leptomeningeal carcinomatosis (LMC) secondary to metastatic breast cancer (MBC) has increased in incidence with improved systemic disease control. Current treatment options include radiation therapy (to symptomatic sites) and systemic treatment [intrathecal (IT) or intravenous (IV) chemotherapy]. Methotrexate (MTX), thiotepa and cytarabine are the most commonly used IT agents, while high-dose MTX is the most common IV regimen. While IT treatments are generally well tolerated, complications like chemical meningitis, leukoencephalopathy, etc. occur. LMC may cause a breakdown in the blood–brain barrier and thus allow systemic agents to penetrate; however, efficacy is reported only for agents administered at high doses (MTX). We report our institution’s experience in using IV thiotepa as treatment for LMC secondary to MBC. We conducted a retrospective chart review of 13 patients with MBC who developed LMC and treated with IV thiotepa at our institution. It was administered at 40 mg/m2 every 21 days; median number of thiotepa cycles administered was 5 with the major dose-limiting toxicity being myelosuppression. Four had partial response, 3 had stable disease and 6 had progressive disease. The 6-month survival rate was 69 {\%} and 1-year survival rate was 31 {\%}. Despite retrospective nature of our case series, we found the use of IV thiotepa as sole treatment for LMC in patients with MBC to be well tolerated, easily administered in the ambulatory setting, and with efficacy comparable to the other chemotherapeutic agents commonly used in the treatment of LMC. This regimen warrants further investigation in prospective studies.",
keywords = "Intravenous chemotherapy, Leptomeningeal carcinomatosis, Metastatic breast cancer, Thiotepa",
author = "Jaspreet Chahal and Stopeck, {Alison T} and Kathryn Clarke and Livingston, {Robert B} and Pavani Chalasani",
year = "2015",
month = "9",
day = "27",
doi = "10.1007/s10072-015-2259-1",
language = "English (US)",
volume = "36",
pages = "1691--1693",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia",
number = "9",

}

TY - JOUR

T1 - Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis

T2 - case series

AU - Chahal, Jaspreet

AU - Stopeck, Alison T

AU - Clarke, Kathryn

AU - Livingston, Robert B

AU - Chalasani, Pavani

PY - 2015/9/27

Y1 - 2015/9/27

N2 - Leptomeningeal carcinomatosis (LMC) secondary to metastatic breast cancer (MBC) has increased in incidence with improved systemic disease control. Current treatment options include radiation therapy (to symptomatic sites) and systemic treatment [intrathecal (IT) or intravenous (IV) chemotherapy]. Methotrexate (MTX), thiotepa and cytarabine are the most commonly used IT agents, while high-dose MTX is the most common IV regimen. While IT treatments are generally well tolerated, complications like chemical meningitis, leukoencephalopathy, etc. occur. LMC may cause a breakdown in the blood–brain barrier and thus allow systemic agents to penetrate; however, efficacy is reported only for agents administered at high doses (MTX). We report our institution’s experience in using IV thiotepa as treatment for LMC secondary to MBC. We conducted a retrospective chart review of 13 patients with MBC who developed LMC and treated with IV thiotepa at our institution. It was administered at 40 mg/m2 every 21 days; median number of thiotepa cycles administered was 5 with the major dose-limiting toxicity being myelosuppression. Four had partial response, 3 had stable disease and 6 had progressive disease. The 6-month survival rate was 69 % and 1-year survival rate was 31 %. Despite retrospective nature of our case series, we found the use of IV thiotepa as sole treatment for LMC in patients with MBC to be well tolerated, easily administered in the ambulatory setting, and with efficacy comparable to the other chemotherapeutic agents commonly used in the treatment of LMC. This regimen warrants further investigation in prospective studies.

AB - Leptomeningeal carcinomatosis (LMC) secondary to metastatic breast cancer (MBC) has increased in incidence with improved systemic disease control. Current treatment options include radiation therapy (to symptomatic sites) and systemic treatment [intrathecal (IT) or intravenous (IV) chemotherapy]. Methotrexate (MTX), thiotepa and cytarabine are the most commonly used IT agents, while high-dose MTX is the most common IV regimen. While IT treatments are generally well tolerated, complications like chemical meningitis, leukoencephalopathy, etc. occur. LMC may cause a breakdown in the blood–brain barrier and thus allow systemic agents to penetrate; however, efficacy is reported only for agents administered at high doses (MTX). We report our institution’s experience in using IV thiotepa as treatment for LMC secondary to MBC. We conducted a retrospective chart review of 13 patients with MBC who developed LMC and treated with IV thiotepa at our institution. It was administered at 40 mg/m2 every 21 days; median number of thiotepa cycles administered was 5 with the major dose-limiting toxicity being myelosuppression. Four had partial response, 3 had stable disease and 6 had progressive disease. The 6-month survival rate was 69 % and 1-year survival rate was 31 %. Despite retrospective nature of our case series, we found the use of IV thiotepa as sole treatment for LMC in patients with MBC to be well tolerated, easily administered in the ambulatory setting, and with efficacy comparable to the other chemotherapeutic agents commonly used in the treatment of LMC. This regimen warrants further investigation in prospective studies.

KW - Intravenous chemotherapy

KW - Leptomeningeal carcinomatosis

KW - Metastatic breast cancer

KW - Thiotepa

UR - http://www.scopus.com/inward/record.url?scp=84940452488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940452488&partnerID=8YFLogxK

U2 - 10.1007/s10072-015-2259-1

DO - 10.1007/s10072-015-2259-1

M3 - Article

C2 - 25990104

AN - SCOPUS:84940452488

VL - 36

SP - 1691

EP - 1693

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 9

ER -